Research progress on combined immune checkpoint inhibitors for the treatment of pa-tients with driver gene-negative non-small cell lung cancer brain metastasis
Research progress on combined immune checkpoint inhibitors for the treatment of pa-tients with driver gene-negative non-small cell lung cancer brain metastasis
Non-small cell lung cancer(NSCLC)is the most common histological lung cancer type and is associated with distant metastases in approximately 66%of patients at the time of diagnosis.The brain is a common site of metastasis,and intracranial involvement is detected in approximately 13%of patients at the initial diagnosis.This severely affects quality of life and leads to a poor prognosis.Targeted therapy in patients with driver gene-positive NSCLC brain metastases achieves better intracranial control rates;however,treatment options for pa-tients with driver gene-negative NSCLC brain metastases are limited.In recent years,with the expansion of immunotherapy,immune check-point inhibitors(ICIs)have been widely used in clinical practice.The therapeutic modality of ICIs combined with radiotherapy shows promise in the treatment of patients with driver gene-negative NSCLC brain metastases.This article reviews the clinical research progress of radio-therapy combined with immunotherapy in patients with sensitive driver gene-negative NSCLC brain metastases,the aim of providing a refer-ence for available clinical treatment options.
维普
万方数据